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ABSTRACT
Objective: To investigate differences between young
children, adolescents and adults with chronic fatigue
syndrome/myalgic encephalomyelitis (CFS/ME).
Study design: Comparison of clinical cohorts from 8
paediatric and 27 adult CFS/ME services in the UK and
a paediatric randomised controlled trial from the
Netherlands. Outcome measures include: fatigue (the
UK—Chalder Fatigue Scale); Disability (the UK—SF-36
physical function subscale; the Netherlands—CHQ-
CF87); school attendance, pain, anxiety and depression
(the UK—Hospital Anxiety & Depression Scale, Spence
Children’s Anxiety Scale; the Netherlands—Spielberger
State-Trait Anxiety Inventory for Children, Children’s
Depression Inventory); symptoms; time-to-assessment;
and body mass index. We used multinomial regression
to compare younger (aged <12 years) and older (aged
12–18 years) children with adults, and logistic
regression to compare UK and Dutch adolescents.
Results: Younger children had a more equal gender
balance compared to adolescents and adults. Adults
had more disability and fatigue, and had been ill for
longer. Younger children were less likely to have
cognitive symptoms (OR 0.18 (95% CI 0.13 to 0.25))
and more likely to present with a sore throat (OR 1.42
(1.07 to 1.90). Adolescents were more likely to have
headaches (81.1%, OR 1.56 (1.36% to 1.80%)) and
less likely to have tender lymph nodes, palpitations,
dizziness, general malaise and pain, compared to
adults. Adolescents were more likely to have comorbid
depression (OR 1.51 (1.33 to 1.72)) and less likely to
have anxiety (OR 0.46 (0.41 to 0.53)) compared to
adults.
Conclusions: Paediatricians need to recognise that
children with CFS/ME present differently from adults.
Whether these differences reflect an underlying
aetiopathology requires further investigation.
Trial registration numbers: FITNET trial registration
numbers are ISRCTN59878666 and NCT00893438.
This paper includes secondary (post-results) analysis
of data from this trial, but are unrelated to trial
outcomes.
INTRODUCTION
The incidence of chronic fatigue syndrome/
myalgic encephalomyelitis (CFS/ME) has
two distinct age peaks, at 10–19 years and
30–39 years.1 Little is known about the
underlying aetiopathology of CFS/ME and
whether it differs between children and
adults. Studies investigating heterogeneity
(phenotypes) in adult2–5 and paediatric6
CFS/ME patients have described some simi-
larities in the delineation of paediatric and
adult CFS/ME phenotypes, based mainly on
the presence/absence of musculoskeletal
pain and ‘acute’ illness symptoms (swollen
glands, sore throat, headache). However,
prognosis is much better in children than in
adults, with 54–94% of children improving
or making a complete recovery from the
illness,7 8 compared with a recovery rate of
not more than 22% in adults.9
No previous study has compared the clin-
ical features of paediatric and adult CFS/ME
patients, which means that clinical guide-
lines, teaching and deﬁnitions for paediatric
Strengths and limitations of this study
▪ This study benefited from large sample sizes,
and data on chronic fatigue syndrome/myalgic
encephalomyelitis (CFS/ME) symptoms and
comorbid mood disorders were collected in the
same way from UK children and adults.
▪ Adults and children were recruited from special-
ist CFS/ME services in the UK and the
Netherlands, so the results may not be generalis-
able to other settings, such as primary care.
▪ Fatigue, disability, pain and mood, were mea-
sured differently in the UK and the Netherlands,
making it difficult to compare these character-
istics directly.
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patients are based on adult descriptions of CFS/ME.
Paediatricians also need more information about
age-related differences between younger and older (ado-
lescent) children. We previously compared 32 primary
school-aged children with adolescents, which showed
that they had similar symptoms at presentation.10
However, the sample size was too small to allow detailed
comparison between the two age groups.
In this study, we used three large clinical cohorts to
compare the characteristics of CFS/ME in children, ado-
lescents and adults. We hypothesised that CFS/ME in
adults would present differently in children compared
to adults, but that younger children would be similar to
older children. We also compared adolescent patients
diagnosed with CFS/ME in the UK with adolescent
patients recruited into a large randomised controlled
CFS/ME treatment trial in the Netherlands,8 to investi-
gate whether paediatric CFS/ME phenotypes might
be robust across different countries and healthcare
settings, as has been demonstrated for adult patients
with CFS/ME.11
METHODS
UK adult and paediatric clinical cohorts
UK data were collected from all NHS specialist services
(see online supplementary material) that participated in
the CFS/ME National Outcomes Database between
August 2004 and October 2014. During this period, clin-
ical assessment data and patient-reported measures were
collected for approximately 10 000 adults and 1500 chil-
dren and young people, from 27 adult and 8 paediatric
CFS/ME services. Patients were included if they were
given a diagnosis of CFS/ME in accordance with
Centers for Disease Control and Prevention (CDC) cri-
teria (to 2007)12 13 or National Institute for Health and
Care Excellence (NICE) guidance (from 2007
onwards).14 These criteria are broadly similar, however,
CDC criteria specify symptom duration of 6 months
compared with 4 months in the NICE guidelines. CDC
criteria also require that patients present with at least
four of eight named symptoms (subjective memory
impairment, sore throat, tender lymph nodes, muscle
pain, joint pain, headaches, unrefreshing sleep and post-
exertional malaise), whereas NICE criteria include these
symptoms (plus ﬂu-like symptoms, dizziness, nausea and
palpitations) for guidance only.
Netherlands paediatric clinical cohort
Children were recruited from paediatricians throughout
the Netherlands for the FITNET trial for adolescents
with CFS/ME, between January 2008 and February
2010.8 Children were included in the trial if they were
aged 12–18 years, had a primary diagnosis of CFS/ME in
accordance with CDC criteria, had severe fatigue
(Checklist Individual Strength (CIS20-R)15 subjective
fatigue subscale score >40) and were physically disabled
(Child Health Questionnaire (CHQ-CF87)16 physical
function subscale score ≤85 or school attendance
≤85%). Children were assessed by a paediatrician and
had screening blood tests to exclude other causes of
fatigue.
Ethical approvals
UK cohorts
The North Somerset and South Bristol Research Ethics
Committee decided that collection and analysis of CFS/
ME patient data constituted service evaluation and did
not require ethical review by a NHS Research Ethics
Committee or approval by NHS Research and
Development ofﬁces (REC reference number 07/
Q2006/48).
Dutch cohort
The FITNET study reviewed and approved by the
Medical Ethical Committee of the University Medical
Centre Utrecht (reference 07/196-K) and the Medical
Ethical Committee of the Radboud University Nijmegen
Medical Centre (reference AMO number 07/105).
Patients and their parents will receive verbal and written
information about the study and informed consent will
be obtained before randomisation. Trial registration:
ISRCTN59878666 and (ClinicalTrials.gov)
NCT00893438.
Clinical and patient-reported measures
Symptoms and comorbidities
In the UK and in the Netherlands, clinicians prospect-
ively collected symptoms used to make a diagnosis of
CFS/ME (cognitive dysfunction, sleep disturbance/unre-
freshing sleep, postexertional malaise, joint pain, muscle
pain, headaches, painful lymph nodes, sore throat,
general malaise/ﬂu-like symptoms, dizziness, nausea and
palpitations).14 13 In the UK, adult and paediatric ser-
vices also prospectively asked patients whether they had
received a diagnosis of depression or anxiety, migraine,
irritable bowel syndrome, Fibromyalgia or Chronic
Regional Pain Disorder. Time to assessment was calcu-
lated as the time from reported symptom onset to assess-
ment in the CFS/ME specialist clinic.
Fatigue
In the UK, fatigue was measured using the Chalder
fatigue scale (range 0–33).17 Internal consistency for this
instrument, calculated by Cronbach’s α, ranges from
0.88 to 0.90.18 In the Netherlands, fatigue was measured
using the ‘subjective fatigue’ subscale of the CIS20-R
(range 8–56). This questionnaire has good reliability, dis-
criminative validity and internal consistency (Cronbach’s
α=0.93).19
Disability
In the UK, disability was measured using the 10-item
physical function subscale of the Short form 36
(SF-36).20 Children scored between 0 (‘yes, limited a
lot’) and 10 (‘no, not limited at all’) for each item, so
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that children with the worst physical function scored 0
while those with good physical function scored 100. In
the Netherlands, physical disability was measured with
the physical functioning subscale of the CHQ-CF87.16
This is scored 0–100% with a lower score indicating
more disability. This assessment tool is reliable and has
been validated with a good internal consistency
(Cronbach’s α=0.86).21
School attendance
School attendance was measured in the UK by asking
how the young person would describe their attendance
as a percentage of expected attendance: ‘None’, ‘About
10% (eg, one half day)’, ‘About 20% (eg, one day)’,
‘About 40% (eg, two days)’, ‘About 60% (eg, three
days)’, ‘About 80% (eg, four days)’ and ‘Full time
(100%)’. In the Netherlands, school attendance was self-
recorded daily for 12 days prior to assessment and aver-
aged. These data were shown to be consistent with
school records.8
Pain
In the UK, a visual analogue pain rating scale was used
to measure pain prior to assessment, with a score of 0
for ‘no pain’ and 100 for ‘pain as bad as possible’. Pain
was categorised as: none (0–4); mild (5–44), moderate
(45–74), severe (75–100). In the FITNET trial, partici-
pants recorded their pain level using a Likert scale
(0–4) at four separate times each day for 12 days prior
to assessment.22
Mood
In the UK, the Hospital and Anxiety Depression Scale
(HADS)23 was used to assess mood in children aged
12 years and older. The HADS is a 14-item inventory
with anxiety and depression subscales.24 Cut-off scores
for HADS depression were >9 for boys, >10 for girls25
and >12 for adults.26 Likewise, the cut-off for identifying
clinical presentations of anxiety symptoms was >12 for
boys, >16 for girls,25 >11 for men and >12 for women.26
In the Netherlands, anxiety was assessed using the
Spielberger State-Trait Anxiety Inventory for Children
(STAIC),27 comprising 20 questions, each on a 3-point
scale. Depression was measured using a Dutch transla-
tion of the 27-item Children’s Depression Inventory
(CDI).28 This instrument has a high degree of internal
consistency, with Cronbach’s α ranging from 0.71 to
0.89.29 Cut-off scores for depression and anxiety were
CDI score >15 and STAIC score >43.8
Statistical analyses
We performed descriptive analyses separately for each of
the four groups: UK children aged <12 years, UK adoles-
cents aged 12–18 years, Dutch adolescents aged 12–
18 years and UK adults (aged 19–65 years). We used
linear regression to estimate differences in disability and
fatigue between UK paediatric and adult patients. We
used multinomial logistic regression analyses to compare
child and adolescent with adult (reference category)
groups, controlling for gender. Binary logistic regression
analyses were used to test for differences between adoles-
cents from the UK and the Netherlands. Inventories
were coded as missing if >1 question was missing. On
the HADS, each seven-item subscale was excluded if
there was more than one question missing. Questions
for which two answers were given were coded as missing.
Total scores were corrected for the number of missing
items. Stata (StataCorp 2013, Stata Statistical Software:
Release 13, College Station, Texas, USA: StataCorp LP)
was used for all analyses.
RESULTS
The UK paediatric cohort comprised 1568 UK adoles-
cents aged 12–18 years and 210 children aged <12 years.
Data on comorbid disorders were collected from 2010,
and these data were available for approximately 900 chil-
dren and adolescents (exact numbers shown in table 1).
Body mass index (BMI) data were available for 37%
(579/1568) of the adolescents and 24% (49/204) of the
younger children. The UK adult cohort comprised
10 675 patients. Symptom data were collected from adults
since 2010, and these data were available for approxi-
mately 7000 adults (exact numbers shown in table 1).
The Dutch adolescent group had almost complete data,
with missing data on BMI in only one patient.
Table 2 shows that younger children (<12 years old)
had a more equal gender balance (56.7% female) com-
pared to adolescents (74.1% and 82.2% in the UK and
the Netherlands, respectively) and adults (77.9%). BMI
was similar in younger children and UK and Dutch ado-
lescents. Duration of illness prior to assessment was
longest in adults (median 36 months), compared to
16 months in UK adolescents and 12 months in UK
primary school-aged children. Disability and fatigue were
similar in younger and older UK children, but adults
had lower mean physical function than adolescents
(–8.2 points (95% CI −9.7 to −6.7 points) on SF-36 phys-
ical function subscale) and higher mean fatigue (2.1
points (1.8–2.4 points) on the Chalder Fatigue Scale.
Adjustment for duration of illness did not change the
difference in fatigue, but did slightly attenuate the differ-
ence in physical function (−6.7 points (−8.2 to −5.2
points)). Mean disability scores were not directly com-
parable between UK and Dutch adolescents because
these had been obtained using different instruments.
Symptoms and comorbidities in young children,
adolescents and adults (UK cohorts)
Table 1 shows that children under 12 (76.5%; OR 0.18
(95% CI 0.13 to 0.25)) are less likely to describe cognitive
symptoms at assessment compared to adults (95.3%) and
adolescents (86.7%). They are also less likely to have pro-
blems with sleeping (85.1% vs 96.4%; OR 0.23 (0.15,
0.34)). They are more likely to present with sore throats
(62.3%; OR 1.42 (1.07% to 1.90%)) compared to adults
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(56.1%). The symptom of postexertional malaise is
slightly less common in those under 12 (95.6%; OR 0.50
(0.25% to 0.99%)) than in adults (97.9%).
Adolescents are more likely to present with headaches
(81.1%; OR 1.56 (1.36% to 1.80%)) compared to
younger children (74.5%) and adults (73.7%).
Adolescents were less likely to describe cognitive symp-
toms (86.7%; OR=0.34 (0.28% to 0.40%)) compared to
adults (95.2%). Tender lymph nodes, palpitations, dizzi-
ness and general malaise, and either mild, moderate or
severe pain (compared to ‘no pain’), were less likely in
teenagers than in adults.
We compared symptoms between younger children
and adolescents. Although younger children were less
likely to present with cognitive dysfunction (OR 0.53
(0.37 to 0.76)), problems with sleep (OR 0.29 (0.19 to
0.47)), or headaches (OR 0.73 (0.52 to 1.03)), they were
more likely to present with recurrent frequent sore
throats (OR 1.29 (0.95 to 1.75)), tender lymph nodes
(OR 1.38 (1.03 to 1.86)) and dizziness (OR 1.62 (1.20 to
2.20)).
Adolescents were more likely to score above the HADS
threshold for depression (27.9% vs 20.3%, OR 1.51
(1.33 to 1.72)), but below the threshold for anxiety
(21%, OR 0.46 (0.41 to 0.53)), compared to adults
(36.2%). However, previous diagnoses of depression and
anxiety (recorded as comorbid by the clinician at time
of assessment) were much less common in children and
adolescents compared to adults, as were all of the other
comorbidities (migraine, irritable bowel syndrome, ﬁbro-
myalgia and regional pain syndrome).
Comparison between adolescents in the UK and the
Netherlands
Table 3 shows that teenagers (aged 12–18 years) with
CFS/ME tended to present with similar symptoms in the
Table 1 Differences in the presence of symptoms among UK children, adolescents and adults with CFS/ME, showing ORs
derived from multinomial logistic regression controlling for gender (adults as reference group unless otherwise indicated)
Symptoms
Younger children
(aged <12 years) Adolescents (aged 12–18 years)
Adults (aged
19–65 years)
N/total (%) OR (95% CI) N/total (%) OR (95% CI) N/total (%)
Cognitive dysfunction 156/204 (76.5) 0.18 (0.13 to 0.25) 1281/1478 (86.7) 0.34 (0.28 to 0.40) 6586/6921 (95.2)
Sore throat 127/204 (62.3) 1.42 (1.07 to 1.90) 860/1482 (58.0) 1.10 (0.98 to 1.24) 3834/6823 (56.1)
Tender lymph nodes 95/203 (46.8) 1.02 (0.77 to 1.36) 601/1469 (40.9) 0.74 (0.66 to 0.83) 3314/6785 (48.8)
Muscle pain 154/204 (75.5) 0.45 (0.32 to 0.63) 1093/1484 (73.7) 0.38 (0.33 to 0.43) 6133/6944 (88.3)
Joint pain 116/205 (56.6) 0.43 (0.32 to 0.57) 895/1483 (60.4) 0.47 (0.42 to 0.53) 5276/6878 (76.7)
Headaches 152/204 (74.5) 1.14 (0.83 to 1.57) 1206/1487 (81.1) 1.56 (1.36 to 1.80) 5063/6870 (73.7)
Sleep dysfunction 171/201 (85.1) 0.23 (0.15 to 0.34) 1394/1462 (95.4) 0.77 (0.59 to 1.02) 6678/6926 (96.4)
Postexertional malaise 196/205 (95.6) 0.50 (0.25 to 0.99) 1444/1485 (97.2) 0.75 (0.53 to 1.07) 6748/6890 (97.9)
Nausea 87/205 (42.4) 0.59 (0.44 to 0.78) 581/1478 (39.3) 0.56 (0.50 to 0.63) 3602/6796 (53.0)
Palpitations 32/113 (28.3) 0.71 (0.47 to 1.08) 329/985 (33.4) 0.85 (0.73 to 0.97) 2533/6771 (37.4)
Dizziness 86/201 (42.8) 1.05 (0.79 to 1.39) 451/1479 (30.5) 0.65 (0.57 to 0.73) 2735/6816 (40.1)
General malaise/flu-like
symptoms
77/116 (66.4) 0.69 (0.47 to 1.02) 661/987 (67.0) 0.68 (0.59 to 0.78) 5131/6835 (75.1)
Pain
No pain (ref cat) 18/180 (10.0) – 166/1349 (12.3) – 635/8779 (7.2)
Mild pain 51/180 (28.3) 0.69 (0.40 to 1.19) 370/1349 (27.4) 0.52 (0.43 to 0.64) 2731/8779 (31.1)
Moderate pain 73/180 (40.6) 0.84 (0.49 to 1.41) 538/1349 (39.9) 0.61 (0.50 to 0.74) 3436/8779 (39.1)
Severe pain 38/180 (21.1) 0.76 (0.43 to 1.35) 275/1349 (20.4) 0.54 (0.44 to 0.67) 1977/8779 (22.5)
Depression symptoms
(HADS)
– – 379/1360 (27.9) 1.51 (1.33 to 1.72) 1916/9420 (20.3)
Anxiety symptoms
(HADS)
– – 285/1357 (21.0) 0.46 (0.41 to 0.53) 3420/9393 (36.4)
Anxiety symptoms
(SCAS)*
56/173 (11.3) 1.09 (0.75 to 1.58) 440/759 (58.0) – –
Comorbid disorders
Depressive disorder 0/10 (0.0) – 61/785 (7.8) 0.17 (0.13 to 0.23) 2195/4488 (32.8)
Anxiety disorder 9/99 (9.1) 0.19 (0.10 to 0.38) 128/782 (16.4) 0.37 (0.30 to 0.45) 2328/6655 (35.0)
Migraine 5/106 (4.7) 0.19 (0.08 to 0.46) 126/818 (15.4) 0.63 (0.52 to 0.77) 1533/6747 (22.7)
Irritable bowel
syndrome
8/106 (7.6) 0.17 (0.08 to 0.35) 67/807 (8.3) 0.18 (0.14 to 0.23) 2312/6749 (34.3)
Fibromyalgia 2/105 (1.9) 0.05 (0.01 to 0.21) 23/813 (2.8) 0.07 (0.05 to 0.11) 1919/6707 (28.6)
Regional pain
syndrome
2/105 (1.9) 0.50 (0.12 to 2.03) 12/808 (1.5) 0.37 (0.21 to 0.67) 261/6667 (3.9)
*Reference group: children aged 12–18 years.
CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; HADS, Hospital and Anxiety Depression Scale; SCAS, Spence Children’s
Anxiety Scale.
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UK and the Netherlands, but postexertional malaise
(97.2% vs 86.7%; OR 5.81 (3.21 to 10.51)), severe pain
(20.4% vs 9%; OR 3.12 (1.49 to 6.54)), depression
(27.9% vs 17%; OR 2.01 (1.26 to 3.22) and anxiety
(21% vs 11.1%; OR 2.62 (1.49 to 4.59)), were more
common in UK adolescents, and headaches (81.1% vs
89.6%; OR 0.54 (0.30 to 0.96)) were less common.
DISCUSSION
This is the ﬁrst study to show that children with CFS/ME
present differently compared to adults with CFS/ME.
Children and adolescents had less fatigue and better
physical function, and were much less likely to have
been given a diagnosis of comorbid illnesses, including
depression and anxiety. Younger children were more
likely to present with sore throat and were less likely to
have sleep or memory problems, often considered car-
dinal symptoms in adults. Adolescents were more likely
to present with cognitive and sleep dysfunction than
were younger children, but less likely to present with
tender lymph nodes and dizziness. Despite differences
in sampling, UK adolescents with CFS/ME were similar
to teenagers in the Netherlands, suggesting that the
symptomatology of paediatric CFS/ME is generalisable
to other populations and is robust across different
healthcare settings.
The main strengths of this study were the large sample
sizes, and the fact that symptoms and comorbid mood
disorders were collected in the same way in UK children
and adults. Adults and children were recruited from spe-
cialist CFS/ME services in the UK and the Netherlands,
so the results may not be generalisable to other settings,
such as primary care. Fatigue, disability, pain and mood
Table 2 Characteristics of UK children, adolescents and adults, and Dutch adolescents
Characteristics
UK (aged
<12 years)
UK (aged
12–18 years)
NL (aged
12–18 years)
UK adults (aged
19–65 years)
N N N N
Age (years), mean (SD) 210 9.3 (2.0) 1568 15.0 (1.8) 135 15.8 (1.3) 10675 40.1 (11.7)
Sex (female), frequency (%) 210 119 (56.7) 1568 1162 (74.1) 135 111 (82.2) 10675 8 (77.9)
BMI (kg/m2), mean (SD) 49 18.5 (3.8) 579 22.1 (6.5) 134 21.0 (2.9) 5598 26.2 (5.7)
Duration of illness (months), median (IQR) 161 12, 7–23 1293 18, 11–28 135 16, 9–28 8488 36, 16–96
Disability*, median (IQR) 178 45, 25–65 1411 50, 33–70 135 52, 48–55 9282 40, 20–60
Fatigue† (Chalder), median (IQR) 190 23, 20–28 1425 25, 22–29 – – 9405 28, 24–31
*UK cohorts used SF-36 physical function subscale to measure disability. The Dutch cohort used the CHQ-CF87 physical function subscale.
†All Dutch children had severe fatigue (CIS20-R subjective fatigue scale score ≥40).
BMI, body mass index; CHQ-CF87, Child Health Questionnaire; SF-36, short form 36.
Table 3 Differences in the presence of symptoms among UK and Dutch adolescents with CFS/ME, showing OR derived
from logistic regression controlling for age and sex (Dutch adolescents as reference group)
UK Netherlands
N Frequency (%) N Frequency (%) OR (95% CI)*
Cognitive dysfunction 1478 1281 (86.7) 135 123 (91.1) 0.77 (0.41 to1.43)
Sore throat 1482 860 (58.0) 135 78 (57.8) 1.03 (0.72 to 1.48)
Tender lymph nodes 1469 601 (40.9) 135 49 (36.3) 1.28 (0.88 to 1.85)
Muscle pain 1484 1093 (73.7) 135 103 (76.3) 0.93 (0.61 to 1.41)
Joint pain 1483 895 (60.4) 135 87 (64.4) 0.86 (0.59 to 1.24)
Headaches 1487 1206 (81.1) 135 121 (89.6) 0.54 (0.30 to 0.96)
Sleep dysfunction 1462 1394 (95.4) 135 129 (95.6) 1.02 (0.43 to 2.42)
Postexertional malaise 1485 1444 (97.2) 135 117 (86.7) 5.66 (3.07 to 10.45)
Pain (ref no pain)† 1349 166 (12.3) 134 22 (16.4) –
Mild pain 1349 370 (27.4) 134 56 (41.8) 0.98 (0.57 to 1.67)
Moderate pain 1349 538 (39.9) 134 44 (32.8) 1.81 (1.04 to 3.13)
Severe pain 1349 275 (20.4) 134 12 (9.0) 3.12 (1.49 to 6.54)
Depression‡ 1360 379 (27.9) 135 23 (17.0) 2.01 (1.26 to 3.22)
Anxiety§ 1357 285 (21.0) 135 15 (11.1) 2.62 (1.49 to 4.59)
*Adjusted for age and sex.
†Pain in UK adolescents was measured on a visual analogue scale, categorised as none (0–4), mild (5–44), moderate (45–74) and severe
(75–100); pain in Dutch adolescents was measured on a 0–4 Likert scale at four separate times each day for 12 days.
‡Depression in UK adolescents was defined as HADS depression score >9 (boys) or >10 (girls); depression in Dutch adolescents was
defined as CDI score >15.
§Anxiety in UK adolescents was defined as HADS anxiety score >12 (boys) or >16 (girls); anxiety in Dutch adolescents was defined as
STAIC score >43.
CDI, Children’s Depression Inventory; CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; HADS, Hospital and Anxiety Depression
Scale; STAIC, Spielberger State-Trait Anxiety Inventory for Children.
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were measured differently in the UK and the
Netherlands, making it difﬁcult to directly compare
these characteristics. Also, while there is evidence for
the validity and reliability of these instruments for adults
diagnosed with CFS/ME,30 their use among paediatric
CFS/ME patients has not been thoroughly evaluated,31
and we cannot assume that scores for adults, adolescents
and children are comparable.
Data for UK adolescents were collected routinely as
this group attended specialist CFS/ME services, whereas
data for Dutch adolescents were obtained from a clinical
trial. In the Dutch cohort, CFS/ME was diagnosed or
conﬁrmed in a tertiary academic hospital setting.
However, since referrals were obtained nationwide from
various sources (general practitioners as well as paedia-
tricians), we consider that our study population was rep-
resentative of the Dutch paediatric CFS/ME population.
The differences in symptom presentation that we
found between younger and older children were not
found in our previous comparison of these age
groups,10 probably because this earlier study was insufﬁ-
ciently powered to detect such differences. It is striking
that the gender balance is more equal in younger chil-
dren (57% female), compared to adolescents (74.1%)
and adults (77.9%). This shift in gender balance is con-
sistent with population data, where an equal gender
balance (49.6% female) has been described in a popula-
tion cohort at age 13 years.32 Studies recruiting teen-
agers from secondary schools have consistently shown a
female-to-male ratio of approximately 3:1,33 34 suggesting
that, during adolescence, the prevalence of CFS/ME
increases in females but not in males.35
Adolescents from the UK and the Netherlands pre-
sented with similar symptoms, although headaches were
less common, and postexertional malaise, severe pain
and mood disorders were more common in UK patients.
The difference in postexertional malaise could be
explained by the fact that this is considered a cardinal
symptom in the UK. The lower prevalence of anxiety and
depression in the Dutch cohort could be because high
scores for mood disorder were a reason for further psy-
chological assessment to exclude primary mood disor-
ders, leading to possible exclusion from the study. Also,
the UK and Dutch cohorts used different instruments to
measure mood (and pain), and this is likely to contribute
to discrepancies when these measures are categorised to
indicate presence/absence (or degree) of symptoms.
Paediatricians need to be aware that children with
CFS/ME present differently from adults with CFS/ME.
Younger children are more likely to present with recur-
rent sore throats and teenagers are likely to present with
headaches. Further research should investigate whether
these differences in presentation reﬂect the underlying
aetiopathology or explain prognostic differences.
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